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Background: Epidermal growth factor receptor (EGFR) activation is important in human epithelial
malignancies, including cutaneous squamous cell carcinoma, lung, colon, pancreatic, and other cancers.
Therapies targeting EGFR are currently used to treat such cancers, but one signiﬁcant drawback to EGFR
inhibitor therapies is the associated skin toxicity. This toxicity usually presents as papular or pustular
folliculitis, dry skin with pruritus and hair and nail abnormalities. The side effects often limit the
usefulness of EGFR inhibitors in cancer treatment. The transcriptional changes caused by EGFR inhibition
in epidermal keratinocytes have not been extensively explored.
Methods: To deﬁne the transcriptional changes caused by inhibition of EGFR in primary human epidermal
keratinocytes, these cells were treated with Tyrphostin AG1478 and treated and control cultures were
compared in parallel, using Affymetrix microarrays. Using meta analysis approaches, the observed
changes were integrated with a large set of already existing data on transcriptional proﬁling in epidermal
keratinocytes.
Results: We found that at the early time points, 1 hour and 4 hours after addition, AG1478 suppresses
expression of genes associated with keratinocyte proliferation, attachment and motility. Apoptosis is
facilitated by both induction of proapoptotic and suppression of antiapoptotic genes. Angiogenesis
signals are suppressed as well. At late time points, 24 hours and 48 hours, EGFR inhibition induces
mitochondrial activity and suppresses splicing and protein trafﬁcking. Certain transcriptional effects of
EGFR inhibition go against the transcriptional effects of retinoids. Surprisingly, at 48 hours, EGFR inhi
bition induces expression of markers of epidermal differentiation.
Conclusion: Our results deﬁne the role of EGF receptor in human keratinocytes and the consequences of
its inhibition.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Among the ﬁrst signaling molecules isolated, epidermal growth
factor (EGF) was named for its capacity to accelerate epidermal
differentiation, as measured by the eye opening in newborn mice.1
Since then, EGF and its receptor (EGFR) have become possibly the
most studied models of extracellular and intracellular signaling
mechanisms.2 5 The binding of EGF to its receptor causes the
receptor to dimerize and consequently activate its cytoplasmic
kinase.6 The activated kinase phosphorylates several substratesgy, NYU School of Medicine,
USA. Tel.: þ1 212 263 5924;
(M. Blumenberg).
iwanese Dermatological Associatiowhich, when phosphorylated, transmit cytoplasmic signals to the
nucleus by activating transcription factors that regulate expression
of many genes.7 In general, the EGF regulated genes promote cell
proliferation and survival, inhibit apoptosis, support chemotactic
migration, while suppressing terminal differentiation.8 Several
ligands in addition to EGF bind and cause activation of EGFR, e.g.,
tumor growth factor a (TGFa), and heparin binding EGF.9 EGFR is
closely related to the ErbB family of protein kinases.10
EGFR is very important in healthy epidermal homeostasis and
disruption of the EGFR signaling has been demonstrated in several
skin diseases.11 In epidermis, EGFR activation contributes to wound
healing, regulates barrier function, suppresses terminal differenti
ation, causes loss of adhesion, induces secreted proteases, etc.11,12
Furthermore, EGFR is often over expressed in cutaneous squa
mous cell carcinomas.13n. Published by Elsevier Taiwan LLC. All rights reserved.
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malignancies, including cancers of the colon, head and neck, lung,
and pancreas.8 Therefore, therapies targeting EGFR by small
molecules or antibodies became a paradigm for treatment of
human cancers.3 Detailed molecular understanding of the kinase
domain led to development of speciﬁc inhibitors, geﬁtinib, erloti
nib, Herceptin (trastuzumab), cetuximab, currently used to treat
breast, lung, ovarian, prostate, head and neck, and other cancers.8,14
These drugs induce tumor regressions proving the importance of
the EGFR signals in some cancers. EGFR targeted treatments avoid
the adverse effects commonly encountered with chemotherapy,
such as nausea, vomiting or hematological toxicities. However,
there are two signiﬁcant drawbacks to EGFR inhibitor therapies: (1)
the intrinsic and acquired resistance to treatment; and (2) the
associated skin toxicity.15,16 The cutaneous reactions to these
treatments usually present as papular or pustular folliculitis erup
tions. Later manifestations include generalized dry skin, pruritus,
and hair and nail abnormalities.17 These side effects often limit the
duration or dosage of EGFR inhibitors in cancer treatment.
Given the importance of cutaneous manifestations of EGFR
targeted therapies, it is surprising that the transcriptional changes
caused by the EGFR inhibition have not been extensively explored in
epidermal keratinocytes. To deﬁne the transcriptional changes
caused by inhibition of EGFR in primary human epidermal kerati
nocytes, we treated these cells with Tyrphostin AG1478, a speciﬁc
inhibitor of the EGFR kinase domain, and compared parallel treated
and control cultures using Affymetrix microarrays. We used publi
cally available, free meta analysis programs to integrate the
observed changes with a large set of already existing data on
transcriptional proﬁling in epidermal keratinocytes.18 23 We found
that Tyrphostin AG1478 inhibits expression of genes associated with
keratinocyte proliferation, attachment and motility and, surpris
ingly, induces expression of markers of epidermal differentiation.
Materials and methods
Human keratinocyte cultures
The growth and treatment of normal human neonatal foreskin
epidermal keratinocytes has been described.18,24,25 Brieﬂy,
keratinocytes were obtained from Dr. M. Simon (Living Skin
Bank, Burn Unit SUNY, Stony Brook, NY, USA) and grown in
a deﬁned serum free keratinocyte growth medium (keratino
cyte SFM; Gibco, Grand Island, NY, USA) supplemented with
2.5 ng/mL epidermal growth factor, 0.05 mg/mL bovine pitui
tary extract, and 1% penicillin/streptomycin at 37C in 5% CO2.
Third passage cells were used at 70e80% conﬂuency. Kerati
nocytes, grown on 100 mm plates, were then treated with 1mM
Tyrphostin AG1478 (Sigma Aldrich, St Louis, MO, USA). The cells
were harvested by scraping 1 hour, 4 hours, 24 hours and 48
hours after treatment.
Preparation of labeled cRNA and GeneChip hybridization
Total RNA was isolated from treated and untreated keratinocytes
with RNeasy kits (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. Approximately 5 mg of total RNA was
reverse transcribed, ampliﬁed, and labeled as described previ
ously.26,27 A 15 mg sample of labeled cRNA was fragmented and
hybridized to HU133Av2 arrays (Affymetrix, Santa Clara, CA, USA).
The arrays were washed, stained with anti biotin streptavidin
phycoerythrin labeled antibody, and scanned using the Agilent
GeneArray scanner system (Hewlett Packard, Palo Alto, CA, USA)
and GeneChip 3.0 software (Affymetrix) to determine the expres
sion of each gene.Array data analysis
Generally, the same data analysis approach as described previously
was used.24 Intensity values from the chips were obtained using
Microarray Suite v. 5.0 (Affymetrix), and scaled by calculating the
overall signal for each array. To compare data from multiple arrays,
the signal of each probe array was scaled to the same target
intensity value of 500 arbitrary units. RMAExpress was used for
background adjustment, quintile normalization, summarization,
and quality analysis. RMAExpress is a program that computes gene
expression summary values and performs quality assessment for
Affymetrix data using the Robust Multichip Average protocol.28
Raw data CEL ﬁles have been deposited in the Gene Expression
Omnibus (GEO) database and are available with the accession
number GSE41680. Regulated genes were selected as differentially
expressed 50% or more between the Tyrphostin AG1478 treated
and the control samples at the same time point. The hierarchical
clustering was performed using TIGR MultiExperiment Viewer
algorithms.29 Annotation and ontology of regulated genes was ob
tained using Database for Annotation, Visualization and Integrated
Discovery (DAVID).30,31 Transcription factor binding sites were also
evaluated using DAVID, in a separate analysis. In addition, lists of
Affymetrix IDs of regulated genes were submitted to DAVID.30
DAVID provided ‘tables’ containing functional and ontological
details of the regulated genes, ‘charts’ containing ontological cate
gories, pathways etc., over represented in the gene lists, ‘clusters’ of
such ontological categories (which identiﬁed redundancies and
overlaps), transcription factors over represented in the promoters
of the genes, as well as sub lists of genes speciﬁc for each onto
logical category. From the ‘tables’, lists of consensus gene symbols
were re formatted, and submitted to the List2Networks program32.
This allowed identiﬁcation of speciﬁc functional commonalities in
various lists of genes, providing the meta analysis results.
Meta-analysis comparisons of regulated genes in keratinocytes
In our previous studies we deﬁned the genes regulated in kerati
nocytes by interferon g (IFNg), interleukin 1 (IL 1), retinoic acid
(RA), EphrinAproteins, and JNK inhibitorSP600125.18,19,21,23,25Using
DAVID, the lists of ofﬁcial symbols of regulatedgenes in those studies
were collected, as were those of the Tyrphostin AG1478 regulated
genes from this study, and these were then submitted to the List2
Network analysis program.32 The programcompares lists formutual
overlaps within speciﬁc categories, e.g., targets of protein kinases,
ontological biological process, or OMIM disease gene association,
returning statistical evaluation of the overlaps. When seven
different relevant categories were analyzed, it was found that ‘Gene
Ontology Biological Process’ is the most informative, probably
because it is the best annotated andmost complete. The matrices of
p values of gene lists overlaps were downloaded, along with
spreadsheets of p values of individual biological processes,
Bonferroni corrected for multiple comparisons.
Results
Induced genes
The complete list of induced and suppressed genes is given in
Supplement Tables 1 and 2. They are too numerous to display in the
text. In addition, the raw data values were deposited in the GEO
database (GSE41680).
In the ﬁrst 1e4 hours after the addition of Tyrphostin AG1478,
perhaps expectedly it being an inhibitor of EGFR signaling,
expression of more genes was suppressed than is induced. Espe
cially at the ﬁrst time point, 1 hour, while many categories were
Table 1 Ontological categories over-represented among the genes induced by the Tyrphostin AG1478 treatment. The selected categories from DAVID analysis are presented,
sorted by the best p-values from each set. Count gives the number of regulated genes in each category and % the percentage of genes in the submitted list that belongs
to that category. Bonferroni correction is used to correct formultiple comparisons. Note that the p-value cut-off of 10 2 is used for the 1 - hour,10 5 for the 4 - hour and
24 - hour, and 10 6 for the 48 - hour time points.
Induced genes Count % p Bonferroni
1 h
Ubl conjugation 6 18.1 2.67E 03 2.53E 01
Nucleosome core 3 9.0 2.88E 03 2.70E 01
Histone core 3 9.0 2.96E 03 2.52E 01
Chromatin 4 12.1 5.99E 03 4.04E 01
Nucleosome 3 9.0 6.15E 03 4.12E 01
Response to abiotic stimulus 5 15.1 6.58E 03 9.53E 01
Apoptosis 6 18.1 7.20E 03 9.65E 01
Programmed cell death 6 18.1 7.66E 03 9.72E 01
4 h
Acetylation 163 38.0 1.25E 37 5.11E 35
Phosphoprotein 280 65.4 6.34E 33 2.59E 30
Cytoplasm 142 33.1 4.94E 16 1.82E 13
Mutagenesis site 87 20.32 2.64E 09 3.98E 06
Cytosol 72 16.8 3.15E 09 1.28E 06
Nucleus 145 33.8 1.17E 08 4.78E 06
Nuclear lumen 74 17.2 2.17E 08 8.82E 06
Membrane-enclosed lumen 86 20.0 8.72E 08 3.54E 05
Ubl conjugation 36 8.4 9.94E 08 4.07E 05
Response to organic substance 46 10.7 1.04E 07 2.39E 04
Non membrane-bound organelle 108 25.2 2.59E 07 1.05E 04
Non membrane-bound organelle 108 25.2 2.59E 07 1.05E 04
Organelle lumen 83 19.3 3.24E 07 1.31E 04
Regulation of apoptosis 48 11 3.65E 07 8.41E 04
Host-virus interaction 23 5 3.69E 07 1.51E 04
Regulation of programmed cell death 48 11.2 4.91E 07 1.13E 03
Melanosome 14 3.2 5.10E 07 2.07E 04
Pigment granule 14 3.2 5.10E 07 2.07E 04
Intracellular organelle lumen 81 18.9 5.14E 07 2.09E 04
Regulation of cell death 48 11.2 5.35E 07 1.23E 03
Nucleotide-binding 69 16.1 6.25E 07 2.55E 04
DNA damage response by p53 apoptosis 7 1.6 1.46E 06 3.36E 03
Positive regulation of apoptosis 31 7.2 1.73E 06 3.99E 03
Positive regulation programmed cell death 31 7.2 1.99E 06 4.59E 03
Positive regulation of cell death 31 7.2 2.19E 06 5.05E 03
24 h
Phosphoprotein 727 48.2 1.33E 20 8.72E 18
Acetylation 320 21.2 2.67E 18 1.75E 15
Cytoplasm 364 24.1 2.09E 13 1.37E 10
Oxidoreductase 87 5.7 5.84E 10 3.82E 07
Mitochondrion 146 9.6 2.34E 09 1.41E 06
Mutagenesis site 229 15.1 3.76E 09 1.44E 05
Mitochondrial membrane 69 4.5 3.80E 09 2.29E 06
Oxidation reduction 101 6.6 1.08E 08 4.10E 05
Mitochondrial inner membrane 57 3.7 1.13E 08 6.82E 06
Organelle envelope 93 6.1 1.92E 08 1.16E 05
Mitochondrial envelope 70 4.6 2.11E 08 1.27E 05
Envelope 93 6.1 2.25E 08 1.36E 05
Oxidoreductase 87 5.7 2.33E 08 4.87E 06
Organelle inner membrane 59 3.9 2.51E 08 1.51E 05
Mitochondrial part 89 5.9 4.64E 08 2.80E 05
Mitochondrion 108 7.1 8.99E 08 5.89E 05
16p13.3 29 1.9 9.53E 08 7.03E 05
Electron transport 25 1.6 4.18E 07 2.74E 04
Vacuole 46 3.0 6.41E 07 3.86E 04
Respiratory chain 20 1.3 1.13E 06 7.38E 04
Lytic vacuole 40 2.6 1.47E 06 8.87E 04
Lysosome 40 2.6 1.47E 06 8.87E 04
Organelle membrane 135 8.9 1.72E 06 1.03E 03
11p15.5 18 1.1 2.19E 06 1.62E 03
48 h
Ectoderm development 40 5.5 1.19E 15 3.20E 12
Epidermis development 38 5.2 2.71E 15 6.98E 12
Desmosome 14 1.9 5.37E 14 2.14E 11
Epithelium development 35 4.8 2.07E 10 5.41E 07
Region of interest: Rod 18 2.5 5.76E 10 1.28E 06
Region of interest: Head 18 2.5 9.17E 10 2.03E 06
Region of interest: Tail 18 2.5 1.44E 09 3.18E 06
Intermediate ﬁlament 18 2.5 2.60E 09 1.39E 06
Region of interest: Linker 1 17 2.3 3.84E 09 8.51E 06
Region of interest: Coil 1B 17 2.3 3.84E 09 8.51E 06
(continued on next page)
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Table 1 (continued )
Induced genes Count % p Bonferroni
Region of interest: Coil 1A 17 2.3 3.84E 09 8.51E 06
Corniﬁed envelope 11 1.5 5.59E 09 2.23E 06
Epidermal cell differentiation 18 2.5 7.58E 09 1.98E 05
Region of interest: Coil 2 16 2.2 8.16E 09 1.81E 05
Region of interest: Linker 12 16 2.2 8.16E 09 1.81E 05
Intermediate ﬁlament 18 2.5 8.66E 09 4.05E 06
Structural constituent of cytoskeleton 18 2.5 1.07E 08 8.80E 06
Cell cell junction 28 3.9 1.90E 08 7.57E 06
Epithelial cell differentiation 24 3.3 2.05E 08 5.38E 05
Structural protein 31 4.3 6.06E 08 1.08E 05
Transmembrane protein 53 7.3 8.64E 08 4.61E 05
Duplication 28 3.9 9.07E 08 4.84E 05
Keratinocyte differentiation 16 2.2 1.00E 07 2.62E 04
Apical junction complex 19 2.6 1.06E 07 4.22E 05
Plasma membrane part 139 19.3 1.15E 07 4.60E 05
Intermediate ﬁlament, conserved site 16 2.2 1.29E 07 1.44E 04
Filament 16 2.2 1.29E 07 1.44E 04
Intermediate ﬁlament protein 16 2.2 1.56E 07 1.74E 04
Palmoplantar keratoderma 9 1.2 1.69E 07 9.02E 05
Table 2 Clustering of ontological categories over-represented among the genes induced by the Tyrphostin AG1478 treatment. To avoid redundancies inherent in the ontology
we used the clustering program of DAVID. Because the individual terms are redundant, for each cluster we chose just the two or three most representative ones. The
enrichment scores are intended to order the relative importance of the gene groups; they evaluate the statistical overlaps of the genes in the categories that constitute
a cluster, and are calculated as the geometric means of the individual scores.
Category Term p Bonferroni
1 h
Cluster 1 Enrichment score: 1.706
GOTERM_BP_FAT Apoptosis 7.20E 03 9.65E 01
GOTERM_BP_FAT Programmed cell death 7.66E 03 9.72E 01
Cluster 2 Enrichment score: 1.647
SP_PIR_KEYWORDS Ubl conjugation 2.67E 03 2.53E 01
UP_SEQ_FEATURE Cross-link: Glycyl lysine isopeptide 4.36E 02 9.99E 01
Cluster 3 Enrichment score: 1.620
GOTERM_BP_FAT Response to light stimulus 3.28E 02 1.00Eþ00
GOTERM_BP_FAT Response to radiation 6.40E 02 1.00Eþ00
4 h
Cluster 1 Enrichment score: 6.088
GOTERM_CC_FAT Nuclear lumen 2.17E 08 8.82E 06
GOTERM_CC_FAT Membrane-enclosed lumen 8.72E 08 3.54E 05
Cluster 2 Enrichment score: 5.679
SP_PIR_KEYWORDS Ubl conjugation 9.94E 08 4.07E 05
SP_PIR_KEYWORDS Isopeptide bond 2.43E 06 9.95E 04
Cluster 3 Enrichment score: 5.242
GOTERM_CC_FAT Non membrane-bound organelle 2.59E 07 1.05E 04
GOTERM_CC_FAT Cytoskeleton 2.79E 03 6.78E 01
Cluster 4 Enrichment score: 4.505
GOTERM_CC_FAT Melanosome 5.10E 07 2.07E 04
GOTERM_CC_FAT Pigment granule 5.10E 07 2.07E 04
Cluster 5 Enrichment score: 4.172
GOTERM_BP_FAT Regulation of apoptosis 3.65E 07 8.41E 04
GOTERM_BP_FAT Positive regulation of programmed cell death 1.99E 06 4.59E 03
Cluster 6 Enrichment score: 3.767
GOTERM_BP_FAT Regulation of apoptosis 3.65E 07 8.41E 04
GOTERM_BP_FAT Negative regulation of programmed cell death 1.71E 02 1.00Eþ00
Cluster 7 Enrichment score: 3.708
GOTERM_CC_FAT Nuclear speck 7.89E 05 3.15E 02
GOTERM_CC_FAT Nuclear body 1.36E 04 5.36E 02
Cluster 8 Enrichment score: 3.325
GOTERM_BP_FAT Intracellular transport 6.73E 06 1.54E 02
GOTERM_BP_FAT Protein targeting 2.00E 05 4.52E 02
Cluster 9 Enrichment score: 3.154
GOTERM_BP_FAT Response to organic substance 1.04E 07 2.39E 04
GOTERM_BP_FAT Response to steroid hormone stimulus 7.43E 02 1.00Eþ00
Cluster 10 Enrichment score: 3.069
GOTERM_BP_FAT DNA damage response resulting in apoptosis 1.46E 06 3.36E 03
GOTERM_BP_FAT Cell aging 2.22E 01 1.00Eþ00
Cluster 11 Enrichment score: 3.008
GOTERM_BP_FAT Cellular response to stress 9.53E 06 2.17E 02
GOTERM_BP_FAT Response to DNA damage stimulus 7.07E 05 1.50E 01
Cluster 12 Enrichment score: 2.670
PANTHER_MF_ALL mRNA splicing factor 7.00E 05 1.11E 02
GOTERM_BP_FAT RNA splicing 2.44E 04 4.31E 01
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Table 2 (continued )
Category Term p Bonferroni
24 h
Cluster 1 Enrichment score: 8.278
SP_PIR_KEYWORDS Oxidoreductase 5.84E 10 3.82E 07
GOTERM_BP_FAT Oxidation reduction 1.08E 08 4.10E 05
Cluster 2 Enrichment score: 6.965
GOTERM_CC_FAT Mitochondrion 2.34E 09 1.41E 06
GOTERM_CC_FAT Mitochondrial membrane 3.80E 09 2.29E 06
Cluster 3 Enrichment score: 5.775
GOTERM_CC_FAT Vacuole 6.41E 07 3.86E 04
GOTERM_CC_FAT Lysosome 1.47E 06 8.87E 04
Cluster 4 Enrichment score: 4.693
GOTERM_CC_FAT Mitochondrial matrix 2.06E 03 7.11E 01
GOTERM_CC_FAT Mitochondrial lumen 2.06E 03 7.11E 01
Cluster 5 Enrichment score: 4.012
GOTERM_CC_FAT Mitochondrial inner membrane 1.13E 08 6.82E 06
SP_PIR_KEYWORDS Respiratory chain 1.13E 06 7.38E 04
Cluster 6 Enrichment score: 3.835
GOTERM_BP_FAT Positive regulation of apoptosis 7.07E 06 2.66E 02
GOTERM_BP_FAT Positive regulation of programmed cell death 8.93E 06 3.35E 02
48 h
Cluster 1 Enrichment score: 7.624
GOTERM_BP_FAT Epidermis development 2.71E 15 6.98E 12
GOTERM_CC_FAT Corniﬁed envelope 5.59E 09 2.23E 06
GOTERM_BP_FAT Keratinocyte differentiation 1.00E 07 2.62E 04
Cluster 2 Enrichment score: 6.277
UP_SEQ_FEATURE Region of interest: Rod 5.76E 10 1.28E 06
SP_PIR_KEYWORDS Intermediate ﬁlament 2.60E 09 1.39E 06
Cluster 3 Enrichment score: 5.506
GOTERM_CC_FAT Desmosome 5.37E 14 2.14E 11
GOTERM_CC_FAT Cell cell junction 1.90E 08 7.57E 06
Cluster 4 Enrichment score: 5.052
GOTERM_MF_FAT Structural molecule activity 1.21E 10 9.94E 08
PANTHER_BP_ALL Cell structure and motility 1.29E 04 2.29E 02
Cluster 5 Enrichment score: 4.529
GOTERM_CC_FAT Insoluble fraction 5.44E 06 2.17E 03
GOTERM_CC_FAT Membrane fraction 6.79E 06 2.71E 03
Cluster 6 Enrichment score: 3.321
GOTERM_CC_FAT Plasma membrane part 1.15E 07 4.60E 05
GOTERM_CC_FAT Plasma membrane 4.49E 03 8.34E 01
Cluster 7 Enrichment score: 3.315
SP_PIR_KEYWORDS Oxidoreductase 9.03E 07 4.82E 04
SP_PIR_KEYWORDS NADP 2.08E 04 1.05E 01
Cluster 8 Enrichment score: 2.825
GOTERM_BP_FAT Response to vitamin A 3.74E 04 6.24E 01
GOTERM_BP_FAT Response to retinoic acid 4.36E 04 6.81E 01
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included ubiquitin conjugation enzymes, which lead to protein
degradation, and the proapoptotic stimuli (Tables 1 and 2).
A much larger set of ontological categories was induced at the 4
hour time point, but the ubiquitin and in particular the pro
apoptosis pathways remain prominent. Many of the induced
proteins are targets for acetylation and phosphorylation; this is an
unexpected ﬁnding and may point to extensive post translational
modiﬁcation in response to EGFR inhibition. Quite unexpectedly,
at 4 hours, induction of the genes for melanosome and pigment
granule components was observed. Upon closer inspection, these
genes encode several organelle constituents and trafﬁcking
proteins (Supplement Table 3).
After 24 hours of EGFR inhibition a large number of mitochon
drial proteins, including oxidoreductases, were induced. Presum
ably, at this time the keratinocytes recognize the widespread
metabolic downturn. One of the responses to such downturns in
metabolism may be to attempt to boost the mitochondrial activity,
presumably to produce more energy.
Quite unexpectedly, at the 48 hour time point induction of the
keratinocyte speciﬁc differentiation markers was observed. Many
of these are keratin proteins; others are components of the corni
ﬁed envelopes (see below). The induced genes members of the
keratin protein family, importantly, include the differentiationspeciﬁc KRT1 and KRT10, but not the basal layer speciﬁc KRT5
and KRT14. These results suggest that in the absence of prolifera
tion signals, and with their metabolism suppressed, the keratino
cytes revert into a different metabolic mode and commence
differentiation and corniﬁcation.
Suppressed genes
The number of Tyrphostin AG1478 suppressed categories is much
more extensive than of the induced genes (Tables 3 and 4). Most
prominent among these are the positive regulators of metabolic
and biosynthetic processes. The positive regulators of cell prolif
eration are particularly targeted for suppression. This was
predictable, because EGF signals cell proliferation, so the inhibition
of EGFR is expected to have an opposite effect.33 The expression of
cell migration associated genes is also suppressed, as is that of focal
adhesion and substrate junctional genes. Interestingly, several of
the negative regulators of apoptosis are also suppressed by Tyr
phostin AG1478. Apparently, the inhibition of EGFR leads to
apoptosis by twomechanisms: induction of proapoptotic genes and
suppression of antiapoptotic genes.
The suppressed ontological categories at 24 hours include the
components of membrane bound organelles, including, curiously
melanosome (Supplement Table 3), as well as nucleotide binding
Table 3 Ontological categories over-represented among the genes suppressed by the Tyrphostin AG1478 treatment. The annotations are the same as in Table 1.
Suppressed genes Count % p Bonferroni
1 h
Phosphoprotein 211 61.5 9.03E 20 3.15E 17
Positive regulation of cellular biosynthetic process 41 11.9 1.27E 08 2.79E 05
Positive regulation of biosynthetic process 41 11.9 1.90E 08 4.15E 05
Cell cycle control 29 8.4 2.57E 08 3.68E 06
Positive regulation of macromolecule metabolic process 46 13.4 3.56E 08 7.81E 05
Regulation of apoptosis 44 12.8 4.43E 08 9.71E 05
Regulation of programmed cell death 44 12.8 5.88E 08 1.29E 04
Regulation of cell death 44 12.8 6.51E 08 1.43E 04
Positive regulation of nitrogen compound metabolic process 38 11.0 7.20E 08 1.58E 04
Positive regulation of macromolecule biosynthetic process 38 11.0 1.06E 07 2.33E 04
Vasculature development 22 6.4 1.51E 07 3.30E 04
Nucleus 117 34.1 3.03E 07 1.06E 04
Blood vessel development 21 6.1 4.47E 07 9.77E 04
Regulation of transcription from RNA polymerase II promoter 39 11.3 5.21E 07 1.14E 03
Mutagenesis site 68 19.8 5.42E 07 6.65E 04
Cytoplasm 96 27.9 6.36E 07 2.22E 04
Negative regulation of macromolecule metabolic process 39 11.3 6.58E 07 1.44E 03
Positive regulation of developmental process 22 6.4 8.23E 07 1.80E 03
Positive regulation of nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
35 10.2 8.65E 07 1.89E 03
Blood vessel morphogenesis 19 5.5 8.97E 07 1.96E 03
Regulation of cell proliferation 40 11.6 1.39E 06 3.04E 03
Positive regulation of cell proliferation 27 7.8 1.40E 06 3.06E 03
Negative regulation of gene expression 30 8.7 2.00E 06 4.37E 03
Negative regulation of cellular biosynthetic process 32 9.3 2.03E 06 4.43E 03
Positive regulation of transcription, DNA-dependent 29 8.4 2.06E 06 4.50E 03
Positive regulation of RNA metabolic process 29 8.4 2.44E 06 5.34E 03
Negative regulation of biosynthetic process 32 9.3 3.16E 06 6.90E 03
Negative regulation of macromolecule biosynthetic process 31 9.0 3.49E 06 7.62E 03
4 h
Phosphoprotein 287 64.0 8.61E 31 3.31E 28
Mutagenesis site 97 21.6 1.01E 11 1.56E 08
Cytoplasm 122 27.2 8.86E 08 3.40E 05
Regulation of phosphate metabolic process 35 7.8 2.86E 07 6.57E 04
Regulation of phosphorus metabolic process 35 7.8 2.86E 07 6.57E 04
Host virus interaction 23 5.1 8.65E 07 3.32E 04
Regulation of protein kinase activity 27 6.0 2.03E 06 4.65E 03
Nuclear lumen 68 15.1 2.46E 06 8.30E 04
Regulation of phosphorylation 32 7.1 2.95E 06 6.76E 03
Pathways in cancer 28 6.2 3.52E 06 4.54E 04
Regulation of kinase activity 27 6.0 3.82E 06 8.74E 03
Regulation of cell motion 19 4.2 4.34E 06 9.91E 03
Positive regulation of developmental process 23 5.1 5.78E 06 1.32E 02
Regulation of cell proliferation 44 9.8 6.33E 06 1.44E 02
Non membrane-bound organelle 103 22.9 6.40E 06 2.16E 03
Intracellular non membrane-bound organelle 103 22.9 6.40E 06 2.16E 03
Cell substrate junction 14 3.1 7.41E 06 2.49E 03
Regulation of transferase activity 27 6.0 8.07E 06 1.84E 02
Regulation of cell migration 17 3.7 1.22E 05 2.77E 02
Focal adhesion 13 2.9 1.45E 05 4.87E 03
Protein phosphorylation 36 8.0 1.93E 05 3.13E 03
Negative regulation of protein kinase activity 12 2.6 1.96E 05 4.41E 02
Membrane-enclosed lumen 78 17.4 2.09E 05 7.02E 03
Cell substrate adherens junction 13 2.9 2.15E 05 7.21E 03
Regulation of MAP kinase activity 15 3.3 2.51E 05 5.59E 02
Negative regulation of kinase activity 12 2.6 2.72E 05 6.04E 02
Endosome 23 5.1 3.05E 05 1.02E 02
24 h
Acetylation 294 35.4 1.97E 59 1.06E 56
Phosphoprotein 515 62.0 2.20E 48 1.18E 45
Cytoplasm 258 31.0 1.15E 23 6.21E 21
Mutagenesis site 183 22.0 1.74E 22 4.48E 19
Nucleotide binding 146 17.5 2.04E 16 1.20E 13
Endoplasmic reticulum 83 10.0 2.94E 16 1.80E 13
Nucleotide binding 200 24.0 1.14E 15 1.11E 12
Membrane-enclosed lumen 175 21.0 1.55E 15 7.99E 13
Intracellular transport 85 10.2 1.89E 14 5.98E 11
Organelle lumen 169 20.3 2.52E 14 1.30E 11
Pigment granule 28 3.3 3.94E 14 2.03E 11
Melanosome 28 3.3 3.94E 14 2.03E 11
RNA-binding 66 7.9 4.71E 14 2.54E 11
ATP-binding 117 14.0 8.92E 14 4.81E 11
Intracellular organelle lumen 164 19.7 1.40E 13 7.20E 11
ATP 38 4.5 7.76E 12 4.18E 09
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Table 3 (continued )
Suppressed genes Count % p Bonferroni
Regulation of apoptosis 89 10.7 2.93E 11 9.30E 08
Host-virus interaction 41 4.9 3.83E 11 2.06E 08
Regulation of programmed cell death 89 10.7 4.91E 11 1.55E 07
Regulation of cell death 89 10.7 5.97E 11 1.89E 07
Endoplasmic reticulum 99 11.9 8.88E 11 4.56E 08
48 h
Acetylation 311 33.9 2.82E 58 1.44E 55
Phosphoprotein 533 58.1 1.08E 38 5.50E 36
Membrane-enclosed lumen 200 21.8 3.67E 23 1.81E 20
Intracellular organelle lumen 193 21.0 1.35E 22 6.66E 20
Organelle lumen 194 21.1 8.12E 22 4.01E 19
RNA-binding 78 8.5 2.04E 18 1.04E 15
Nuclear lumen 156 17.0 1.40E 17 6.93E 15
RNA processing 82 8.9 6.16E 17 3.28E 13
RNA binding 93 10.1 2.27E 15 2.10E 12
RNA splicing, via transesteriﬁcation 38 4.1 7.91E 15 2.33E 11
Nuclear mRNA splicing, via spliceosome 38 4.1 7.91E 15 2.33E 11
RNA splicing, via transesteriﬁcation reactions 38 4.1 7.91E 15 2.33E 11
Ribonucleoprotein complex 73 7.9 9.92E 14 4.90E 11
RNA splicing 51 5.5 1.22E 13 3.59E 10
Cytoplasm 245 26.7 1.52E 13 7.75E 11
Nucleus 297 32.3 1.85E 13 9.44E 11
mRNA processing 53 5.7 1.16E 12 3.42E 09
ATP-binding 121 13.1 2.93E 12 1.50E 09
mRNA splicing 38 4.1 3.26E 12 1.66E 09
Nucleoplasm 99 10.7 5.63E 12 2.78E 09
Ribonucleoprotein complex biogenesis 37 4.0 7.98E 12 2.35E 08
mRNA metabolic process 56 6.1 8.77E 12 2.59E 08
mRNA processing 41 4.4 4.13E 11 2.11E 08
Nucleotide-binding 140 15.2 4.13E 11 2.11E 08
Nucleotide binding 188 20.5 6.42E 11 6.08E 08
Mutagenesis site 161 17.5 1.02E 10 2.45E 07
Cytosol 128 13.9 1.16E 10 5.75E 08
Table 4 Clustering of ontological categories over-represented among the genes suppressed by the Tyrphostin AG1478 treatment. The annotations are the same as in Table 2.
Category Term p Bonferroni
1 h
Cluster 1 Enrichment score: 6.14
Vasculature development 1.51E 07 3.30E 04
Blood vessel development 4.47E 07 9.77E 04
Cluster 2 Enrichment score: 5.70
Regulation of apoptosis 4.43E 08 9.71E 05
Negative regulation of programmed cell death 4.22E 05 8.83E 02
Cluster 3 Enrichment score: 5.58
Regulation of apoptosis 4.43E 08 9.71E 05
Regulation of programmed cell death 5.88E 08 1.29E 04
Cluster 4 Enrichment score: 5.32
Regulation of apoptosis 4.43E 08 9.71E 05
Positive regulation of programmed cell death 2.91E 05 6.18E 02
Cluster 5 Enrichment score: 4.52
Regulation of transcription from RNA polymerase II promoter 5.21E 07 1.14E 03
Negative regulation of transcription 9.18E 06 1.99E 02
Cluster 6 Enrichment score: 3.79
Positive regulation of cellular biosynthetic process 1.27E 08 2.79E 05
Positive regulation of biosynthetic process 1.90E 08 4.15E 05
4 h
Cluster 1 Enrichment score: 4.36
Regulation of cell motion 4.34E 06 9.91E 03
Regulation of cell migration 1.22E 05 2.77E 02
Cluster 2 Enrichment score: 4.30
Non membrane-bounded organelle 6.40E 06 2.16E 03
Cytoskeleton 2.97E 03 6.33E 01
Cluster 3 Enrichment score: 4.23
Nuclear lumen 2.46E 06 8.30E 04
Nucleolus 8.28E 05 2.75E 02
Cluster 4 Enrichment score: 4.21
Blood vessel development 3.32E 05 7.35E 02
Angiogenesis 1.71E 04 3.25E 01
Cluster 5 Enrichment score: 3.41
Programmed cell death 4.36E 05 9.52E 02
Negative regulation of apoptosis 3.22E 03 9.99E 01
(continued on next page)
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Table 4 (continued )
Category Term p Bonferroni
Cluster 6 Enrichment score: 3.38
Regulation of phosphate metabolic process 2.86E 07 6.57E 04
Regulation of kinase activity 3.82E 06 8.74E 03
Cluster 7 Enrichment score: 3.17
Cell-substrate junction 7.41E 06 2.49E 03
Focal adhesion 1.45E 05 4.87E 03
Cluster 8 Enrichment score: 3.08
Cytoskeleton 8.09E 05 3.06E 02
Cytoskeletal protein binding 2.32E 03 7.72E 01
Cluster 9 Enrichment score: 3.00
Regulation of apoptosis 1.11E 04 2.25E 01
Positive regulation of apoptosis 5.66E 04 7.27E 01
24 h
Cluster 1 Enrichment score: 11.40
Membrane-enclosed lumen 1.55E 15 7.99E 13
Nuclear lumen 1.85E 10 9.52E 08
Cluster 2 Enrichment score: 10.50
Pigment granule 3.94E 14 2.03E 11
Melanosome 3.94E 14 2.03E 11
Cluster 3 Enrichment score: 10.27
Endoplasmic reticulum 2.94E 16 1.80E 13
Endoplasmic reticulum 8.88E 11 4.56E 08
Cluster 4 Enrichment score: 9.75
Nucleotide-binding 2.04E 16 1.20E 13
ATP-binding 8.92E 14 4.81E 11
Cluster 5 Enrichment score: 7.30
Chaperone 4.35E 10 8.70E 08
Protein folding 4.01E 08 7.62E 06
Cluster 6 Enrichment score: 6.70
RNA-binding 4.71E 14 2.54E 11
mRNA splicing 1.58E 09 8.50E 07
Cluster 9 Enrichment score: 5.14
Regulation of apoptosis 2.93E 11 9.30E 08
Regulation of programmed cell death 4.91E 11 1.55E 07
48 h
Cluster 1 Enrichment score: 15.44
GO:0031974wmembrane-enclosed lumen 3.67E 23 1.81E 20
GO:0031981wnuclear lumen 1.40E 17 6.93E 15
Cluster 2 Enrichment score: 10.73
RNA processing 6.16E 17 3.28E 13
RNA splicing 1.22E 13 3.59E 10
Cluster 3 Enrichment score: 7.38
ATP-binding 2.93E 12 1.50E 09
Nucleotide-binding 4.13E 11 2.11E 08
Cluster 4 Enrichment score: 7.02
Protein transport 2.22E 10 1.13E 07
Intracellular transport 2.87E 10 8.46E 07
Cluster 5 Enrichment score: 6.26
Mitochondrion 1.09E 09 5.57E 07
Mitochondrial part 5.58E 08 2.76E 05
Cluster 6 Enrichment score: 6.18
Pre-mRNA processing 6.61E 09 1.36E 06
mRNA splicing 9.64E 08 1.99E 05
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advanced both by the induction of proapoptotic, and by suppres
sion of the antiapoptotic genes at later time points as well. Inter
estingly, after 48 hours, many RNA processing enzymes, splicing
factors were suppressed; this follows the general suppression of
transcription. Essentially, after 48 hours of blocked signals from
EGFR the cells are shutting down, relinquishing all metabolic
and biosynthetic processes and attempting to commence
differentiation.
The induced differentiation markers
The induction of epidermal differentiation markers in response to
EGFR inhibition was particularly intriguing. Components of the
corniﬁed envelopes, involucrin, desmoplakin, envoplakin, peri
plakin, and periplakin interacting protein, kazrin were induced at
the 48 hour time point (Table 5). Also induced is the epidermaltransglutaminase, the enzyme responsible for crosslinking the
corniﬁed envelope proteins. Several small proline rich proteins are
also induced, as are certain differentiation speciﬁc markers that are
not major components of the corniﬁed envelopes, but are essential
for the proper corniﬁcation, such as kallikrein proteases. Interest
ingly, enzymes of lipid metabolism, such as fatty acid binding
protein 5 and aldehyde dehydrogenase 3 family, member A2, the
genemutated in Sjögren Larsson syndrome, are also induced at this
time.
Regulatory mechanisms involved: transcription factors
The transcriptional changes in response to EGFR inhibition,
presumably, reﬂect the changes in the activity of transcription
factors (TFs). Using the DAVID program, the putative TFs respon
sible were identiﬁed, i.e., those TFs with binding sites statistically
over represented in the regulated genes.30 The most prominent in
Table 5 Epidermal differentiation genes induced at 48 hours. Marker ‘CE’ in the ﬁrst
column indicates those genes known to encode components of the corni-
ﬁed envelopes.
Gene name
E74-like factor 3, epithelial-speciﬁc)
Kruppel-like factor 4
POU class 3 homeobox 1
Aldehyde dehydrogenase 3 family, member A2
Calmodulin-like 5
Cellular retinoic acid binding protein 2
Collagen, type I, a1
Collagen, type V, a1
Collagen, type V, a2
CE Corneodesmosin
CE Cystatin A (steﬁn A)
CE Cystatin E/M
CE Desmoplakin
CE Envoplakin
Fatty acid binding protein 5 (psoriasis-associated)
Forkhead box N1
CE Involucrin
Kallikrein-related peptidase 5
Kallikrein-related peptidase 7
Kazrin
CE Keratin 1
CE Keratin 10
Keratin 13
Keratin 15
Keratin 16; keratin type 16-like
Keratin 17; keratin 17 pseudogene 3
Keratin 34
Keratin 6A
Keratin 6B
Keratin 83
Keratin 9
Mucosal vascular addressin cell adhesion molecule 1
CE Periplakin
CE Sciellin
Serine peptidase inhibitor, Kazal type 5
CE Small proline-rich protein 1A
CE Small proline-rich protein 1B (corniﬁn)
CE Small proline-rich protein 2B
CE Small proline-rich protein 3
CE Transglutaminase 1 K polypeptide epidermal type I
Table 6 Transcription factor binding sites over-represented in the promoters of the
Tyrphostin AG1478 regulated genes. Top: Induced genes, Bottom: sup-
pressed genes. The top p-value sites are presented for the genes regulated at
the ﬁrst two time points, 1 hour and 4 hours. Count columns give the
number of genes with respective sites, % the percentage of submitted genes
that have the binding sites.
Transcription factor Count % p
Induced
PAX5 13 86.6 4.05E 03
GCNF 13 86.6 4.62E 03
NGFIC 9 60.0 8.73E 03
SOX9 11 73.3 9.28E 03
RORA1 11 73.3 1.01E 02
Suppressed
AP1 147 76.1 1.47E 13
NFE2 95 49.2 3.92E 09
FOXO1 105 54.4 6.66E 09
LMO2COM 134 69.4 1.24E 08
P53 139 72.0 1.96E 06
SRY 98 50.7 3.25E 06
TAXCREB 119 61.6 3.35E 06
CMYB 99 51.2 3.51E 06
BACH2 100 51.8 4.00E 06
HFH1 103 53.3 4.26E 06
PAX5 122 63.2 6.99E 06
AML1 155 80.3 1.01E 05
FREAC7 107 55.4 1.57E 05
BACH1 110 56.9 1.59E 05
PAX3 98 50.7 2.39E 05
AP1FJ 73 37.8 2.48E 05
MYCMAX 130 67.3 2.79E 05
PAX2 123 63.7 3.16E 05
E4BP4 97 50.2 3.22E 05
TATA 115 59.5 3.52E 05
ATF 76 39.3 3.73E 05
FOXO4 115 59.5 4.77E 05
YY1 141 73.0 5.05E 05
MYOGNF1 103 53.3 5.39E 05
GATA1 158 81.8 5.61E 05
AHRARNT 112 58.0 5.67E 05
ELK1 107 55.4 7.02E 05
CEBPB 116 60.1 7.77E 05
FREAC4 100 51.8 8.70E 05
NRF2 71 36.7 8.70E 05
HLF 90 46.6 9.77E 05
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(AP1) TF (Table 6). This was expected because functional AP1 sites
have been found in many marker genes expressed in epidermal
keratinocytes.34 38 AP1 consists of a dimer containing one member
of the Fos and one of the Jun family of proteins.39 The expression of
the individual members of the AP1 protein family in different
epidermal layers is still controversial.35,38,40 AP1 binds to its
consensus palindromic binding site TGA(GC)TCA.41 The same
sequence is recognized by additional TFs, such as NF E2, BACH1 and
BACH2. The BACH proteins are basic leucine zipper transcription
factors, can function both as transcription activators and as tran
scriptional repressors and regulate transcription of genes involved
in G1/S and G2/M phases of the cell cycle; they form heterodimers
with MafK proteins and are known to be sensitive to oxidative
stress.42,43
The genes suppressed at early time points additionally contain
a statistical overabundance of FOXO1, p53, SRY, cMyb, as well as
additional TF binding sites. These TFs may function in the EGFR
dependent transcription regulation in epidermal keratinocytes.
E74 like factor 3 was also induced (Table 5). This epithelia speciﬁc
Ets transcription factor plays a role in differentiation and may be, in
part, responsible for the induction of epidermal differentiation
markers noted above.
Fewer TF binding sites reached statistical signiﬁcance in the
induced genes (Table 6). This was, of course, expected becausemuch fewer genes are induced than suppressed by the addition of
Tyrphostin AG1478 to keratinocyte cultures.
Regulatory mechanisms involved: microRNAs
One of the ways to regulate mRNA levels, besides the activity of
TFs, is by microRNAs (miRNAs).44 To explore the role of miRNAs
in response to Tyrphostin AG1478 addition, it was determined
which miRNAs target the differentially expressed genes using
List2Genes program 32. While in total 155 miRNAs were
analyzed, the targets of only a few miRNAs reached high statis
tical relevance (Table 7). Some of these miRNAs have been
implicated in processes related to ones affected by Tyrphostin
AG1478, described above. For example, miR 124, miR 26AB,
miR 1/206 and miR 320 inhibit proliferation, oncogenesis,
metastasis, and epithelial mesenchymal transition.45 50 All of
these processes are activated by EGF and, conversely, inhibited
by Tyrphostin AG1478. These results suggest that the inhibitors
of the EGFR signaling may act in part through miRNAs in ﬁghting
cancers.
Targets for miR 19 are also over represented among the sup
pressed genes at the early time points, 1 hour and 4 hours. This
miRNAwas described as a suppressor of inﬂammation via negative
regulation of TLR2, and as exacerbating inﬂammation by activating
NFkB.51,52 It is thus unclear whether it plays a role in EGFR signal
Table 7 MicroRNAs (miRNAs) with targets over-represented in the regulated genes. Only the miRNAs with targets of statistical probability better than 10 6 are presented. The
total number of miRNAs examined is 155.
miRNA Tyr UP 1 h 4 h 24 h 48 h TyrDN 1 h 4 h 24 h 48 h
MIR-124/506 3.28E 08
MIR-19 5.05E 07 2.73E 07
MIR-23AB 3.27E 08
MIR-26AB/1297 9.75E 08
MIR-30A/30A-5P/30B/30B-5P/
30CDE/384-5P
5.75E 07
MIR-1/206 3.58E 12 4.99E 13
MIR-144 8.62E 07
MIR-320/320ABCD 3.51E 07 4.23E 07
Table 8 Overlaps of the lists of genes regulated by Tyrphostin AG1478 with those regulated by other extracellular agents. We show overlaps with genes regulated by EGF, the
JNK inhibitor SP600125, interleukin-1, interferon-g, tumor necrosis factor-a, retinoic acid and the ﬁve EphrinA proteins. UP denotes induced, DN suppressed genes.
The overlaps with p-value better than 10 9 are marked with gray; the identities are in black ﬁelds. Downward arrows mark high overlaps in both the induced and the
suppressed gene lists. Upward arrows mark antiparallel overlaps, i.e., genes induced by Tyrphostin AG1478, but suppressed by other agents, and vice versa.
Treatment Tyr UP 1h 4h 24h 48h TyrDN 1h 4h 24h 48h
Tyr UP 1 h 0.00 1.65E-18 2.02E-12 1.66E-13 4.64E 01 5.73E 01 7.29E 02 2.50E 01
Tyr UP 4 h 1.66E-15 0.00 2.24E-26 5 30E-37 5.15E 07 3.32E 02 2.24E 154 2.25E 19
Tyr UP 24 h 3.89E-09 1.57E-22 0.00 1 51E 202 1.71E 02 9.57E 03 1.00E+00 1.09E 01
Tyr UP 48 h 5.51E-11 8.93E-35 2.63E-245 0.00 5.60E 04 6.82E 01 1.00E+00 1.00E+00
Tyr DN 1 h 4.67E 01 3.96E 07 1.15E 02 3.91E 04 0.00 5.13E-127 5.87E-69 1.01E-26
Tyr DN 4 h 5.75E 01 3.32E 02 6.30E 03 6.85E 01 1.62E-120 0.00 2.37E-79 8.45E-33
Tyr DN 24 h 8.69E 02 5.85E 136 1.00E+00 1.00E+00 2.82E-60 7.55E-72 0.00 4.90E-85
Tyr DN 48 h 2.66E 01 5.09E 18 1.02E 01 1.00E+00 5.61E-24 4.38E-30 1.22E-83 0.00
EGF UP 1&4 h 1.05E 01 1.13E 04 8.65E 03 3.13E 05 5.62E-82 3.50E-90 1.46E-51 2.11E-08
EGF UP 24&48 h 1.00E+00 1.65E 03 2.75E 01 2.79E 02 3.62E-48 1.46E-57 3.20E-64 5.05E-08
EGF DN 1&4 h 2.51E 06 2.96E 04 6.84E-12 7.30E-33 5.67E 01 8.15E 01 6.42E 01 1.00E+00
EGF DN 24&48 h 9.34E 08 1.72E-13 1.08E-54 1.26E-70 6.41E-10 1.86E 03 8.91E 04 1.48E 01
SP600125 UP 1&4 h 1.66E-08 1.43E 06 5.51E-11 1.73E-14 9.56E 05 9.90E 02 1.53E 02 3.76E 01
SP600125 UP 24&48 h 3.93E 02 8.97E 06 9.15E-10 1 59E-22 2 37E 07 5.05E 08 3.13E 04 5.18E 01
SP600125 DN 1&4 h 2.82E 02 7.11E 02 1.00E+00 8.84E 01 5 47E-34 1.73E-30 1.99E-18 3.19E 03
SP600125 DN 24&48 h 2.29E 01 3.38E 03 8.71E 01 7.40E 01 1.38E 05 1.63E 03 1.53E-13 1.46E 02
IL1 UP 1 h 2.25E 03 1.81E 08 6.29E 03 1.47E 03 7.77E-46 6.78E-39 1.99E-33 1.12E-17
IL1 UP 4 h 9.40E 02 5.00E-11 2.96E 06 2.36E 07 7.32E-13 1.14E-29 3.39E-24 8.90E-11
IL1 UP 24 h 2.53E 01 3.30E-24 9.10E 01 3.50E 01 2.20E-43 3.18E-62 1.67E-115 3.38E-55
IL1 UP 48 h 2.97E 02 5.24E-14 6.56E 02 3.00E 01 2.54E-44 1.70E-58 1.42E-83 1.61E-49
IL1 DN 1 h 3.48E 02 5.26E 05 8.27E-31 1.03E-39 4.24E 01 5.34E 01 6.21E 01 8.80E 01
IL1 DN 4 h 2.37E 02 3.28E 02 6.91E 08 1.94E-15 9.49E-22 8.20E-11 5.27E 07 5.48E 01
IL1 DN 24 h 6.11E 06 5.83E 01 9.29E-15 1.82E-28 9.74E 01 1.00E+00 1.00E+00 1.00E+00
IL1 DN 48 h 6.51E 04 1.84E 03 8.67E-25 3.38E-44 4.54E 01 1.00E+00 1.00E+00 1.00E+00
Interferon-  UP 4.13E 01 4.64E 02 4.67E 08 5.87E-12 1.58E-08 6.82E-12 2.94E-11 1.67E 01
Interferon-  DN 2.44E 02 1.10E 08 7.91E-11 5.80E-15 1.99E 03 1.48E 01 7.23E 07 5.20E 03
TNF UP 1 h 1.77E 03 1.19E 05 2.59E 06 7.58E-09 3.08E-46 2.10E-44 2.29E-29 3.10E 05
TNF UP 4 h 1.89E 05 2.27E-09 2.81E-60 7.26E-63 3.59E-22 1.84E-46 6.53E-18 2.33E 04
TNF UP 24 h 8.43E 04 4.02E 07 2.80E-37 8.08E-38 2.13E-25 2.90E-21 3.68E-12 5.44E 03
TNF UP 48 h 1.03E 03 2.96E-11 5.37E-36 2.12E-23 1.82E-43 1.41E-41 4.62E-33 4.80E-14
TNF DN 1 h 4.20E 05 2.91E 06 1.98E-19 2.76E-18 2.20E 02 3.59E 02 8.02E 05 1.26E 01
TNF DN 4 h 7.39E 03 3.81E 08 5.20E 02 2.66E 02 2.41E-17 8.81E 07 4.83E-20 5.56E-10
TNF DN 24 h 1.73E 03 1.40E-18 1.89E 06 1.18E 03 1.40E-11 1.12E-13 9.75E-52 4.90E-40
TNF DN 48 h 1.73E 03 1.40E-18 1.89E 06 1.18E 03 1.40E-11 1.12E-13 9.75E-52 4.90E-40
RA UP 1 h 3.41E 06 7.55E 03 1.42E-10 5.51E-18 2.91E 06 5.69E 05 5.66E 05 6.20E 01
RA UP 4 h 2.60E 01 3.41E 03 2.61E 02 2.29E 04 3.54E-91 8.50E-111 5.70E-59 4.94E-24
RA UP 24 h 1.23E 01 4.98E-26 6.91E 01 3.12E 02 2.05E-34 4.77E-48 1.41E-110 8.87E-36
RA UP 48 h 6.53E 04 4.24E-09 7.84E-21 1.83E 05 2.75E-10 3.79E-17 9.01E-11 4.30E-12
RA DN 1 h 3.73E 03 1.82E-17 5.18E-10 6.98E-08 3.98E-57 9.18E-34 2.09E-48 3.08E-13
RA DN 4 h 1.08E-09 4.16E-39 5.73E-55 3.70E-42 2.54E 08 7.93E 05 4.48E-10 9.24E 03
RA DN 24 h 4.95E 06 7.57E-15 2.31E-124 1.84E-99 2.82E 06 5.21E 04 7.96E 05 2.30E 02
RA DN 48 h 3.21E 02 1.62E-55 1.34E-45 1.33E-63 1.30E-30 1.32E-24 3.54E-77 6.26E-13
EFNA UP 3.48E 01 5.29E 04 7.88E-22 3 94E-60 2.13E 01 7.92E 01 9.76E 01 6.83E 01
EFNA DN 2.51E 01 4.21E 04 5.62E 01 7.55E 01 5 00E-35 6.93E-41 6.92E-46 1.68E 03
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Figure 1 Time course scheme of processes regulated by EGFR inhibitor in
keratinocytes.
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keratinocytes.
Regulatory mechanisms involved: processes and pathways
The List2Network program was used for analysis of biological
processes and pathways affected by Tyrphostin AG1478.32 The
Bonferroni corrected lists of: (1) gene ontology biological process,
(2) molecular function terms, (3) OMIM disease associations, (4)
GenMAPP pathways, (5) KEGG pathways, and (6) kinase targets is
presented in Supplement Table 4. These results, in general, conﬁrm
the results described in Tables 1e4. It should be noted, however,
that the OMIM disease association and KEGG pathways analysis
identiﬁed chronic myeloid leukemia, gastric, colorectal, and
bladder cancer genes suppressed by Tyrphostin AG1478. These
results reﬂect the role of EGFR in many human neoplasms.
Meta-analysis: correlating Tyrphostin AG1478 regulated genes
with genes regulated in keratinocytes by other extracellular
signals
The list of genes regulated by Tyrphostin AG1478 was compared
with lists of genes identiﬁed previously as regulated by extra
cellular signals, namely EGF, IL1, TNFa, IFNg, RA, EphrinAs and
SP600125, a speciﬁc inhibitor of JNK.18,19,21,23,25 The List2Net
work program was used for comparisons and the matrix of p
values for overlapping of related lists was collected.32 The
matrix, which depicts statistical signiﬁcance of the overlaps
between lists, is presented here in Table 8. As expected, the
genes induced at all four time points created a congruous cate
gory, as did the genes suppressed at all four time points. The
overlaps were found with extremely high probability, p values
reaching 10245 and 10127 (Table 8). These congruities are
indicated by gray shading. Again as expected, the genes sup
pressed by Tyrphostin AG1478 strongly correlate with those
induced by EGF and vice versa. This antiparallel, reciprocal
relation is highlighted by the opposing directions of arrows,
downward versus upward (Table 8). Similarly, there is a strong
parallel relationship between Tyrphostin AG1478 regulated and
the SP600125 regulated genes. SP600125 inhibits JNK, one of the
activators of Jun, the AP1 family member. However, inhibitors of
EGFR can activate JNK in keratinocytes and other cell lines,53
which would suggest independent pathways for the Tyrphostin
AG1478 and SP600125 mediated promotion of differentiation.
This issue requires further study.
Comparing lists of Tyrphostin AG1478 regulated genes with
those regulated by other signals revealed very interesting
patterns: IL 1 and IFNg have ‘antiparallel’ effects, i.e., generally
the processes induced by IL 1 and IFNg are suppressed by Tyr
phostin AG1478 and vice versa. This suggests that IL 1 and IFNg
activate keratinocytes, similar to EGF, but Tyrphostin AG1478
inhibits keratinocyte activation. Much more complex are the
relationships between Tyrphostin AG1478 and TNFa, and Tyr
phostin AG1478 and RA. No clear parallel or antiparallel rela
tionship can be discerned: certain genes are regulated in common
at one time point but others are regulated in opposite directions at
other time points (Table 8). Particularly intriguing is the
comparisonwith the RA regulated genes: genes induced at 1 hour
after RA addition are induced by Tyrphostin AG1478; at later time
points RA regulated genes overlap the Tyrphostin AG1478
regulated ones in both the parallel and even more the antipar
allel fashion.
Certain genes induced by Tyrphostin AG1478 are also induced
by EphrinAs, and the same is true for the suppressed categories
(Table 8). Because EphrinAs induce keratinocyte differentiationmarkers,18,54 which are also induced by Tyrphostin AG1478, the
pro differentiation effects of EGFR inhibition parallel those of
EphrinA activation.
Discussion
To deﬁne comprehensively the molecular effects of inhibiting EGFR
in human epidermal keratinocytes we used transcriptional
proﬁling, identiﬁed the regulated genes and compared these with
genes regulated in keratinocytes by other extracellular signals, and
with genes regulated by EGF. Both expected and unexpected classes
of regulated genes were found (Fig. 1). Inhibition of EGFR induces
apoptosis, as expected; both the proapoptotic signals are induced
and the antiapoptotic ones are suppressed. Numerous genes related
to motility and substrate attachment are suppressed by Tyrphostin
AG1478. Similarly, the biosynthetic metabolic processes are sup
pressed, overall transcription and translation are dampened and
various transport processes reduced.Unexpectedly, the inhibition of EGFR induces expression of
keratinocyte differentiation markers. Keratinocyte proliferation
and differentiation are mutually incompatible: apparently, inhib
iting cell proliferation diverts the cells into a differentiation
pathway and consequently certain differentiation markers are
induced. These include many of the ‘classical’ markers, involucrin,
keratins KRT1 and KRT10, but also lipid biosynthesis enzymes,
lipids being an essential component of the stratum corneum. While
both EGF and RA inhibit keratinocyte differentiation, Tyrphostin
AG1478 promotes this process. Indeed, we ﬁnd signiﬁcant disparity
between the effects of Tyrphostin AG1478 and RA: genes induced
by one are suppressed by the other and vice versa.
As expected, the effects of EGFR inhibition oppose those invoked
by EGF addition. Interestingly, EGFR inhibition also opposes certain
of the effects of IL 1 and IFNg. These extracellular signals partici
pate in keratinocyte activation, complex and multifaceted
responses in wound healing, inﬂammation and hyperproliferation
processes. We are surprised that similar antiparallel relationships
were not found between the EGFR inhibition and the TNFa effects.
TNFa is one of the best known and most studied activators of
keratinocytes, important in psoriasis and other inﬂammatory
diseases. Apparently, different aspects of keratinocyte activation
are regulated by EGF, IFNg, IL 1, and TNFa, the well known parallels
between IL 1 and TNFa notwithstanding.
Conversely, there are striking parallels with the effects of JNK
inhibition: SP600125 and Tyrphostin AG1478 cause similar tran
scriptional changes in keratinocytes, in particular, changes associ
ated with epidermal differentiation. In a canonical pathway, EGFR
activates the ERK signaling cascades. Active ERKs result in
A. Gazel, M. Blumenberg / Dermatologica Sinica 31 (2013) 107 119118activation of, among others, the AP1 transcription factors. JNK is
a component of one of the ERK pathways and it also activates AP1.
However, inhibitors of EGFR, apparently through unknown, EGFR
independent mechanisms, can activate JNK in keratinocytes 53.
We note that AP1 transcription factor binding sites are signiﬁcantly
over represented among both the Tyrphostin AG1478 suppressed
and the SP600125 suppressed genes. Therefore we propose that
among the signaling pathways inhibited by Tyrphostin AG1478 are
those activating the AP1 proteins.
In conclusion, we present here the transcriptional effects of
EGFR inhibition in the epidermis, and compare these with tran
scriptional proﬁle changes in the same cell type by different
extracellular signaling molecules.Acknowledgments
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